[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"staphylococcus-aureus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:staphylococcus-aureus":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,47,59,88,118,147,173,196],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":28,"conditions":29,"keywords":31,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100053463","phase-1-a-study-to-evaluate-azd7760-safety-and-pharmacokinetics-in-healthy-adults-phase-i-and-adults-with-end-stage-kidney-disease-on-hemodialysis-with-a-central-venous-catheter-phase-iia-100053463",false,"NCT06749457","A Study to Evaluate AZD7760 Safety and Pharmacokinetics in Healthy Adults (Phase I) and Adults With End-stage Kidney Disease on Hemodialysis With a Central Venous Catheter (Phase IIa)","A Phase I\u002FIIa Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of AZD7760 in Healthy Participants and in Patients With End-stage Kidney Disease Receiving Hemodialysis Through a Central Venous Catheter","PEAK","Inclusion Criteria:\n\nPhase I:\n\n* Participant must be 18 to 55 years of age (inclusive), at the time of signing the informed consent.\n* Body weight ≥ 45 kilograms (kg) and ≤ 110 kg and Body Mass Index (BMI) within the range ≥ 18.0 to ≤ 30.0 kilograms per square meter (kg\u002Fm2) (inclusive) at screening.\n* Healthy participants with no clinically significant concomitant diseases or medications (except for those specifically permitted by the protocol) according to medical history, physical examination, screening safety laboratory tests, and screening parameters, as perthe judgement of the investigator.\n\nPhase IIa:\n\n* Participant must be ≥ 18 years of age at the time of signing the informed consent.\n* Participants who meet all of the following disease status requirements:\n\n  1. Diagnosed with End-stage kidney disease (ESKD).\n  2. Requiring hemodialysis through a tunneled central venous catheter as the primary vascular access for hemodialysis.\n  3. Receiving hemodialysis for treatment of ESKD for at least 90 days before randomization.\n  4. At least 3 previous dialysis sessions using current dialyzer.\n  5. Receiving adequate hemodialysis based on a single-pool Kt\u002FV measurement \\> 1.2 within the last 30 days.\n  6. No new medications have been added to the participant's regimen in the last 2 weeks prior to dosing. 'New medication' is defined as any medication that has not been prescribed or used by the participant previously (including formulation changes). Medication previously prescribed or used by the participant with dose adjustments is allowed and not considered as new medication for the purpose of this study.\n  7. Not taking long-term systemic antibiotics with activity against S aureus.\n\nExclusion Criteria:\n\nPhase I:\n\n* Known hypersensitivity to any component of the study intervention\n* Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of monoclonal antibodies (mAbs).\n* Clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following intramuscular injections or venipuncture.\n* Aspartate Aminotransferase (AST) or alanine Aminotransferase (ALT) above 1.5 × upper limit of normal (ULN) at screening. Testing may be repeated once at the investigator's discretion.\n* Estimated glomerular filtration rate \\\u003C 90 mL\u002Fmin\u002F1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration equation at screening.\n* Hemoglobin or platelet count below the lower limit of normal at screening. Testing may be repeated once at the investigator's discretion.\n* White blood cell counts outside normal reference ranges unless judged by the investigator to be out of range given the known variation in white blood cell count reference interval by ethnicity. Testing may be repeated once at the investigator's discretion.\n* History of malignancy other than treated non-melanoma skin cancers or locally treated cervical cancer in the previous 5 years.\n* Any laboratory value in the screening panel that, in the opinion of the investigator, is clinically significant or might confound analysis of study results. Testing may be repeated once at the investigator's discretion.\n* Any clinically significant abnormalities on 12-lead electrocardiogram (ECG) at screening, as judged by the investigator.\n* Acute (time-limited) illness, including fever ≥ 38 °C (100.4 °F), one day prior to or on day of planned dosing; participants excluded for transient acute illness may be dosed if illness resolves within the 28-day Screening Period or may be rescreened once.\n* Known or suspected congenital or acquired immunodeficiency, or receipt of immunosuppressive therapy, including any course of glucocorticoid therapy exceeding 2 weeks of prednisone or equivalent at a dose of 20 mg daily or every other day within 6 months prior to screening.\n* Any condition that has the potential to increase clearance of the study intervention (eg, protein loss conditions such as severe enteropathies, or plasmapheresis).\n* Blood drawn in excess of a total of 450 milliliters (mL) (1 unit) for any reason within 2 months prior to screening.\n* Absence of suitable veins for blood sampling and administration of study intervention.\n* Any other condition that would compromise safety of the participants.\n* Any condition that, in the opinion of the investigator, might interfere with evaluation of the study intervention or interpretation of participant safety or study results.\n\nPhase IIa:\n\n* Known hypersensitivity to any component of the study intervention.\n* History of allergic disease or reactions likely to be exacerbated by any component of the study intervention as listed in dose formulation section.\n* Previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of mAbs.\n* Hemoglobin \\\u003C 9 g\u002FdL at screening considered by the investigator to be due to acute condition(s). Testing may be repeated once at the investigator's discretion.\n* Serum albumin of \\\u003C 3 g\u002FdL at screening considered by the investigator to be due to acute condition(s). Testing may be repeated once at the investigator's discretion.\n* Myocardial infarction, acute coronary syndrome, stroke, seizure, or a thrombotic\u002Fthromboembolic event (eg, deep vein thrombosis or pulmonary embolism, but excluding vascular access thrombosis) within 90 days prior to randomization.\n* Known S aureus infection within 90 days of study entry.\n* Known acute viral or bacterial infection or symptoms\u002Fsigns consistent with such an infection within the 21 days prior to infusion or study intervention. Mild intercurrent viral illness with a temperature of 38.1 °C (100.6 °F) or less does not require exclusion, if in the judgement of the investigator this illness will not interfere with the evaluation of the mAb.\n* Participants with malignancy undergoing chemotherapy.\n* Scheduled date for living donor kidney transplant.\n* Plans to switch to peritoneal dialysis within the primary endpoint time period (181 days).\n* Participants with a scheduled calendar date for transition to arteriovenous graft or arteriovenous graft in place and maturing.\n* Participants with a scheduled calendar date for transition to arteriovenous fistula, or arteriovenous fistula in place and maturing, with anticipated use of fistula within 90 days.",true,"ALL","18 Years","55 Years",{"count":22,"type":23},231,"ESTIMATED","INTERVENTIONAL",[26,27],"PHASE1","PHASE2","The purpose of this study is to evaluate the safety and pharmacokinetics (PK) of AZD7760 when given as an intravenous infusion to healthy participants (Phase I) or participants with end-stage kidney disease receiving hemodialysis through a central venous catheter (Phase IIa).",[30],"Staphylococcus Aureus",[32,33],"Bloodstream infection","End-stage kidney disease","RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":38},"2024-12-30",{"date":42,"type":23},"2028-01-07",{"name":44,"class":45},"AstraZeneca","INDUSTRY",43,{"id":48,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":49,"targetDuration":4,"studyType":24,"phases":50,"briefSummary":28,"conditions":51,"keywords":52,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":53,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":57,"leadSponsor":58,"locationsCount":46},"100573682",{"count":22,"type":23},[26,27],[30],[32,33],"2026-06-10",{"date":55,"type":38},"2026-06-11",{"date":40,"type":38},{"date":42,"type":23},{"name":44,"class":45},{"id":60,"slug":61,"hasResults":11,"nctId":62,"briefTitle":63,"officialTitle":64,"acronym":4,"eligibilityCriteria":65,"healthyVolunteers":17,"sex":18,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":4,"studyType":24,"phases":70,"briefSummary":71,"conditions":72,"keywords":75,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":87},"100537863","phase-1-comparing-single-versus-repeat-nmt-on-the-diversity-of-the-neonatal-nasal-microbiome-100537863","NCT06283355","Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome","Comparing Single Versus Repeat Parent-to-Child Nasal Microbiome Transplant on Seeding, Engraftment, and Diversity of the Neonatal Nasal Microbiome","Inclusion Criteria:\n\nNeonate:\n\n1. Neonate has anticipated NICU length of stay \\> 7 days\n2. Neonate ≥25 weeks gestation\n3. At least one parent\u002Fadult provider not colonized with S. aureus (as determined by baseline screening)\n4. Neonate is not colonized with S. aureus on baseline screening\n\nParent\u002FAdult provider:\n\n1\\. Parent\u002FAdult provider is able to provide informed consent\n\nExclusion Criteria:\n\nNeonate:\n\n1. Neonate has had a prior clinical or surveillance culture grow S. aureus\n2. Neonate is a ward of the State\n3. Neonate with antenatal suspicion for immunodeficiency (e.g. sibling with known immunodeficiency, genetic syndrome with known associated immunodeficiency)\n4. Neonate cannot have nasal swabs collected (due to anatomic or other clinical intervention, including nasal packing)\n\nParent\u002FAdult provider:\n\n1. Parent\u002Fadult provider had positive COVID-19 test in prior 21 days\n2. Parent\u002Fadult provider with signs or symptoms of respiratory illness (e.g. runny nose, congestion, fever, cough)\n3. Parent\u002Fadult provider has been in close contact with someone in the last 7 days who had a respiratory viral infection, like the cold or the flu?\n4. Parent\u002Fadult provider tests positive on baseline screening test for S. aureus nasal colonization.\n5. Parent\u002Fadult provider tests positive on baseline screening test for a respiratory pathogen.\n6. Parent\u002Fadult provider is not able to provide written informed consent\n7. Parent\u002Fadult provider is not able to be present at the bedside at the time of intervention.\n8. Parent\u002Fadult provider has history of chronic sinusitis, cystic fibrosis, or an infection with a multi-drug resistant organism.\n9. Inability or unwillingness to complete the Donor questionnaire or a positive response to any question on the Donor questionnaire","0 Years","60 Years",{"count":69,"type":23},175,[26],"This study aims to determine whether a parent-to-child nasal microbiota transplant (NMT) can seed and engraft parental organisms into the neonatal microbiome and increase the neonatal microbiome diversity.",[30,73,74],"Microbial Colonization","Neonatal Infection",[76],"microbiome","2026-06-04",{"date":79,"type":38},"2026-06-08",{"date":81,"type":38},"2024-09-03",{"date":83,"type":23},"2026-12-31",{"name":85,"class":86},"Johns Hopkins University","OTHER",1,{"id":89,"slug":90,"hasResults":11,"nctId":91,"briefTitle":92,"officialTitle":93,"acronym":94,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":96,"targetDuration":4,"studyType":24,"phases":98,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":87},"100551230","echocardiography-versus-no-echocardiography-in-s-aureus-bacteraemia-and-virsta-score--3-100551230","NCT06457386","Echocardiography Versus no Echocardiography in S. Aureus Bacteraemia and VIRSTA Score \u003C 3","Echocardiography Versus no Echocardiography in Individuals With Staphylococcus Aureus Bacteremia and a VIRSTA Score \u003C3: a Non-inferiority Randomized Controlled Trial","VIRSTA-VAL","Inclusion criteria\n\n* Volunteers over 18 years of age;\n* Hospitalized with at least one blood culture positive for Staphylococcus aureus;\n* At the time of inclusion, negative control blood culture performed 48 hours after the first Staphylococcus aureus blood culture collection;\n* VIRSTA score \\\u003C 3; Exclusion criteria\n* Patient with catheter colonization without SAB, defined as positive blood cultures only through vascular access device specimen;\n* Patient referred to the hospital for the management of IE;\n* Contra indication to transthoracic echocardiography (TTE);\n* Echocardiography already performed before inclusion (TTE or TEE) for the current SAB;\n* Pregnancy;\n* Patient under guardianship or trusteeship.\n* Absence of written informed consent from the patient\n* No affiliation to social security (beneficiary or assignee)\n* Subject already involved in another interventional clinical research for which echocardiography must be done\"",{"count":97,"type":23},700,[99],"NA","Staphylococcus aureus is the most frequent cause of both healthcare-associated and community-acquired bloodstream infections worldwide. Infective endocarditis (IE) has been detected in 5-17% of cases and is a determinant of poor prognosis. The investigators developed a score (the VIRSTA score) based on patients' characteristics to rule out IE with high confidence (negative predictive value (NPV) above 99%) in patients with SAB. This score, with a cut-off of 3 has been externally validated by two international studies which have also established its high NPV. The 2023 European society of cardiology (ESC) guidelines state that echocardiography should be considered in all patients with Staphylococcus aureus bacteremia (SAB) using risk scores (including VIRSTA score) to guide the use or not of echocardiography. While recommended, the investigators think that VIRSTA score must be evaluated in terms of patients' outcome.",[30,102,103],"Bacteremia","Infective Endocarditis",[105,106,107,108],"VIRSTA score \u003C 3","Staphylococcus aureus bacteraemia","Echocardiography","Infective endocarditis","2025-11-19",{"date":111,"type":38},"2025-11-24",{"date":113,"type":38},"2025-05-14",{"date":115,"type":23},"2028-12",{"name":117,"class":86},"Assistance Publique - Hôpitaux de Paris",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":24,"phases":128,"briefSummary":130,"conditions":131,"keywords":133,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":87},"100564777","phase-4-decolonization-efficacy-of-polyhexanide-vs-mupirocin-100564777","NCT06633588","Decolonization Efficacy of Polyhexanide vs. Mupirocin","Surgical Prophylaxis: Assessing Decolonization Efficacy of Polyhexanide Versus Mupirocin and Chlorhexidine in Decolonizing Staphylococcus Aureus Preoperatively in Elective Spine Surgery (SPADE): A Pilot Randomized Controlled Trial","SPADE","Inclusion Criteria:\n\n* Age over 18 years\n* Scheduled for elective spinal surgery\n* Colonized with Staphylococcus aureus\n* Informed consent provided\n\nExclusion Criteria:\n\n* Emergency spine surgery\n* Methicillin-resistant Staphylococcus aureus (MRSA) or mupirocin-resistant S. aureus\n* Known allergies to products used in the trial\n* Pregnant or breastfeeding women\n* Recent antibiotic therapy (within 14 days)\n* Known non-compliance, substance abuse, or psychological disorders\n* Participation in another antimicrobial trial within the last 30 days",{"count":127,"type":23},24,[129],"PHASE4","This pilot randomized controlled trial evaluates the feasibility, tolerability, and preliminary efficacy of a decolonization regimen using polyhexanide in reducing Staphylococcus aureus colonization in the preoperative phase of elective spine surgery, compared to the standard mupirocin and chlorhexidine regimen. The trial involves 24 participants randomized into two groups: one receiving polyhexanide and the other receiving mupirocin and chlorhexidine. The primary outcome is the randomization rate, with secondary outcomes including other feasibility outcomes, tolerability, and efficacy measures such as the reduction in S. aureus colony-forming units (CFUs) and changes in the nasal and skin microbiome composition.",[30,132],"Colonization, Asymptomatic",[134,135,136],"Staphylococcus aureus colonization","Spinal surgery","decolonization","2025-05-21",{"date":139,"type":38},"2025-05-28",{"date":141,"type":38},"2025-05-01",{"date":143,"type":23},"2027-04-30",{"name":145,"class":146},"Swiss Paraplegic Research, Nottwil","NETWORK",{"id":148,"slug":149,"hasResults":11,"nctId":150,"briefTitle":151,"officialTitle":152,"acronym":4,"eligibilityCriteria":153,"healthyVolunteers":11,"sex":18,"minAge":19,"maxAge":154,"enrollmentInfo":155,"targetDuration":4,"studyType":24,"phases":157,"briefSummary":158,"conditions":159,"keywords":161,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":171,"locationsCount":87},"100446525","phase-4-interleukin-4ra-blockade-by-dupilumab-decreases-staphylococcus-colonization-and-increases-microbial-diversity-in-crswnp-100446525","NCT05094570","Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP","Interleukin-4Ralpha Blockade by Dupilumab Decreases Staphylococcus Aureus Colonization and Increases Microbial Diversity in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)","Inclusion Criteria: • Adults, ages 18-65\n\n* History of CRSwNP including subjects with AERD\n* Sinonasal culture demonstrating staph aureus at visit 1\n* History of FESS with patent sinus ostia sufficient to obtain culture and tissue samples from the middle meatus\n* Asthma, if present, should be well controlled\n* Atopic dermatitis, if present, should be well controlled\n* Use of nasal saline irrigation and stable dosing (\\>1 month) of topical corticosteroids is permitted\n* Intent of the physicians caring to start dupilumab therapy as part of subject's standard of care\n* Subject meets FDA approved criteria for the use of dupilumab for nasal polyps\n\nExclusion Criteria:\n\n* Concurrent serious medical problem\n* Uncontrolled asthma (ACT \\\u003C20 at screening visit)\n* Recent (within 60 days) use of oral corticosteroids\n* Recent (within 60 days) urgent care, ED visit, or hospitalization for asthma\n* Current smoker or has smoked \\>10 pack-years\n* Biologic therapy including asthma biologic therapy in last 3 months\n* Recent (within 1 month) change in CRS medical treatment (topical steroids, surfactants, irrigation protocol, etc. including changes in delivery volume or delivery methodology)\n* Recent (within 6 weeks) upper respiratory infection\n* Antibiotics within 6 weeks\n* Pregnant or breast-feeding women\n* Any contraindication to the use of dupilumab including hypersensitivity on previous administration","65 Years",{"count":156,"type":23},20,[129],"Hypothesis: The investigators hypothesize that in patients with CRSwNP who demonstrate sinus colonization with staphylococcus aureus, the administration of dupilumab will be associated with decreased staph colonization and an increase in microbial diversity.\n\nPrimary Objective will be to demonstrate that dupilumab reduces staphylococcus aureus (phyla firmicutes) abundance while increasing microbial diversity in patients with CRSwNPs who are culture positive for staph aureus at enrollment.\n\nSecondary Objectives will be to correlate reduction in Staph aureus abundance and improved bacterial diversity with increased expression of anti-microbial proteins (ß-defensins1-4) and cathelicidin LL-37. In addition, the investigators will correlate improvements in microbial diversity\u002Fdecreased staph abundance with clinical improvements as assessed via questionnaires and objective\u002Fsubjective smell function and also as improvements in cellular\u002Fimmune T2 inflammation as assessed by reduced expression of T2 cytokines\u002Fchemokines and eosinophil\u002Feosinophil-derived proteins.",[160,30],"Nasal Polyps",[162,163,164],"Nasal polyps","Staph aureus","Interleukin-4\u002F-13","2025-03-26",{"date":167,"type":38},"2025-04-01",{"date":169,"type":38},"2022-09-01",{"date":83,"type":23},{"name":172,"class":86},"University of Virginia",{"id":174,"slug":175,"hasResults":11,"nctId":176,"briefTitle":177,"officialTitle":178,"acronym":179,"eligibilityCriteria":180,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":181,"targetDuration":4,"studyType":24,"phases":183,"briefSummary":184,"conditions":185,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":195},"100538417","phase-1-first-in-man-single-dose-and-multiple-dose-study-to-evaluate-the-safety-tolerability-and-efficacy-ofhy-133-100538417","NCT06290557","First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy ofHY-133","A Randomized Double-blind Placebo-controlled First-in-man Single-dose and Multiple Dose Study to Evaluate the Safety, Tolerability and Efficacy of a Recombinant Chimeric Bacteriophage Endolysin HY-133 With an Extended Phase to Evaluate Effects of the Nasal Microbiome","HY-133","Inclusion Criteria\n\n* Must be ≥ 18 years at the time of signing the informedconsent.\n* Understand and voluntarily sign an informed consent document prior to any study related\n* assessments\u002Fprocedures.\n* Nasal colonization with methicillin-susceptible S. aureus (MSSA)\n* Female Subject of childbearing potential1 and male subjects with female partner of childbearing potential1 is willing to use highly effective contraceptive methods during treatment until end of study at D15\n\nExclusion Criteria\n\n* Nasal colonization with methicillin-resistant S. aureus (MRSA)\n* Nasal traumata including nose penetrating foreign bodies (e.g. piercings)\n* Presence of any significant morbidity, e.g. Diabetes, cardiovascular disease\n* Acute or known chronic diseases of the nose or the paranasal sinuses\n* Acute or known chronic diseases of other parts of the respiratory tract\n* Running nose due to other reasons (e.g. allergic diseases)7. Positive serological HIV, hepatitis A, B or C test. In case of positive HBsAg, volunteer must provide prove of hepatitis B vaccination, otherwise volunteer must be excluded.\n* Women during pregnancy and lactation.\n* History of hypersensitivity to the investigational medicinal product or to any drug with similar chemical structure or to any excipient present in the pharmaceutical form of the investigational medicinal product.\n* Participation in other clinical trials or observation period of competing trials, in the 12 weeks prior to screening.\n* Acute or chronic, clinically significant psychiatric, hematologic, pulmonary, cardiovascular, or hepatic or renal functional abnormality as determined by the Investigator based on medical history, physical exam, and\u002For laboratory screening test\n* Systemic antibiotic treatment in the 12 weeks prior to screening.\n* Intranasal eradication therapy in the 12 weeks prior to screening.",{"count":182,"type":23},52,[26],"In this clinical trial we will test a new approach for decolonization of S. aureus.\n\nAs innovative product HY-133 a recombinant chimeric bacteriophage endolysin will be sprayed in both nostrils of healthy subjects once or five times in one day. To avoid possible bias the subjects will be randomized 3:2 verum vs placebo, moreover the subject as well as the investigator will be blinded to the group assigned.",[30],"2024-12-03",{"date":188,"type":38},"2024-12-06",{"date":190,"type":38},"2024-07-10",{"date":192,"type":23},"2026-07-01",{"name":194,"class":86},"University Hospital Tuebingen",2,{"id":197,"slug":198,"hasResults":11,"nctId":199,"briefTitle":200,"officialTitle":201,"acronym":4,"eligibilityCriteria":202,"healthyVolunteers":11,"sex":18,"minAge":203,"maxAge":4,"enrollmentInfo":204,"targetDuration":206,"studyType":207,"phases":4,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":87},"100444937","rifampicin-resistance-in-s-aureus-during-and-after-treatment-for-latent-tuberculosis-100444937","NCT05073926","Rifampicin Resistance in S. Aureus During and After Treatment for Latent Tuberculosis","Acquisition and Persistence of Rifampicin Resistance in Staphylococcus Aureus During and After Treatment for Latent Tuberculosis","Inclusion Criteria:\n\n* diagnosed with latent tuberculosis\n* prescribed either 4 months rifampicin or 6-9 months isoniazide\n* informed consent\n\nExclusion Criteria:\n\n* none","16 Years",{"count":205,"type":23},100,"10 Months","OBSERVATIONAL","Two commonly used treatments for latent tuberculosis infection are either 4 months rifampicin or 6-9 months isoniazid. The invistigators will study the risk of acquisition of rifampicin resistance in commensal Staphylococcus aureus in persons treated with rifampicin versus in persons treated with isoniazide. Through repeated swab cultures before, during, and after treatment the investigators will also investigate potential accumulation of mutations associated with rifampicin resistance over time. Finally, household contacts to persons with rifampicin-resistant S. aureus will be examined to investigate whether onward transmission of rifampicin-resistant S. aureus occurs within households.",[210,30],"Latent Tuberculosis",[212,213,214,215,216],"rifampicin","isoniazide","staphylococcus aureus","latent tuberculosis","Drug Resistance, Microbial","2024-07-12",{"date":219,"type":38},"2024-07-15",{"date":221,"type":38},"2021-09-30",{"date":223,"type":23},"2026-12",{"name":225,"class":86},"Region Skane"]